Extended Data Fig. 3: Comparison to semaglutide.
From: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
a–c, DIO mice were treated once-daily via s.c. injections of GLP-1:GIP:Lani or vehicle for 9 days. 2, 10 and 50 nmol kg−1. a, Body weight (n = 8). b, Change in fat and lean mass (n = 8). c, Cumulative food intake (GLP-1:GIP:Lani 10 nmol/kg and 50 nmol/kg, n = 6; all other groups, n = 8). d–i, DIO mice were treated once-daily via s.c. injections of GLP-1:GIP:Lani, semaglutide or vehicle for 16 days. 10 nmol kg−1. d, Body weight (GLP-1:GIP:Lani, n = 6; all other groups, n = 8). e, Cumulative food intake (GLP-1:GIP:Lani, n = 6; all other groups, n = 8). f, Change in fat and lean mass (GLP-1:GIP:Lani, n = 6; all other groups, n = 8). g, Glucose tolerance test at day 16 (Vhcl, n = 8; Semaglutide, n = 7; GLP-1:GIP:Lani, n = 6). h, Fasting blood glucose (GLP-1:GIP:Lani, n = 6; all other groups, n = 8). i, Fasting plasma insulin (GLP-1:GIP:Lani, n = 6; all other groups, n = 8). j–l, DIO mice were treated once-daily via s.c. injections of Lani, GLP-1:GIP, GLP-1:GIP:Lani or vehicle for 14 days. n = 8 each group. 10 nmol kg−1. j, Energy expenditure. k, Respiratory exchange ratio (RER). l, locomotor activity. Data were analysed using one-way ANOVA with Bonferroni post hoc multiple-comparison test (b,f,h) two-way repeated-measures ANOVA (a,c,d,e,g), Kruskall-Wallis test with uncorrected Dunns’s test (i), or Analysis of Covariance (ANCOVA) with body weight as covariate (j). Cumulative food intake (c,e) was assessed per cage in single-or double-house mice. Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. Exact P-values, n-values and detailed statistics are provided in Supplementary Tables 1 and 3 and the Data Source File.
